The Journal of the National Cancer Institute published a study that stated -- a sharp decline in the use of premenopausal hormones was followed by a drop in the rate of breast cancer.

In the recent past, large clinical trials were conducted as part of the Women's Health Initiative that raised concerns about the health risks from hormonal therapies to manage menopausal symptoms. This report led many to stop using the drugs.

Since those reports that were published in 2002, the sharp decline in hormonal drugs has also seen a decline in breast cancer cases. They are not sure if this is the only reason that breast cancer rates have dropped.

The researchers however think the results of the trial provide additional evidence that recent declines in breast cancer incidence may be due in part to a decline in the use of postmenopausal hormones.

The researchers don't seem to know why, but there is a decline in the number of women in the United States age 40 or older who have had mammograms over the last two years.

A study published in the journal Cancer says that during the period from 1987 to 2000, there was a steady increase in women receiving mammograms. They believe this to be somewhat responsible for the increase in breast cancer survival that occurred during that period. Supporting the phrase -- early detection saves lives.

They evaluate the trends in mammography use by a survey that is administered to 35,000 adults called the National Health Interview Survey. The current analysis focused on women who had mammograms in the last two years. The survey showed that in the year 2000, 70 percent of women reported they had a mammogram in the previous two years. In the year 2005, the number was down to 66 percent.

Femara (letrozole) is an aromatase inhibitor that works by suppressing the production of estrogen. In postmenopausal women estrogen is still produced in the body by the adrenal gland. Decreasing this production is a way of decreasing the risk of recurrence.

Tamoxifen on the other hand works by blocking the estrogen receptors on the cancer cell itself resulting in slower growth of the cell or cell death. Tamoxifen can be given to post or premenopausal women but Femara would only be prescribed to women that are postmenopausal. The reason being, is that a premenopausal women will still have estrogen produced by the ovaries. Femara would not be effective in this instance.

A Phase III clinical trial that is ongoing shows preliminary results that Femara is superior than Tamoxifen in women with early stage disease that are postmenopausal. The results of the study were published in the Annals of Oncology.

Sad news for the female cancer survivors out there with decreased libido. Topical testosterone creams do not seem to work. A decrease in libido is a common problem among female cancer survivors.

When is our Viagra going to come out?

Seriously though, its tough being in a position where chemotherapy wrecks havoc on our bodies and ruins our libido -- then we are told there is nothing we can do about it. I'm a breast cancer survivor with estrogen positive disease so it is not recommended that I use any supplemental estrogen.

Testosterone cream was tried out in a study, published in the Journal of the National Cancer Institute, that included 150 post-menopausal breast cancer survivors. Half received the testosterone cream and the other half a placebo. The study found that there was no statistical difference in libido between the testosterone cream and placebo groups.

However, all women in the study did show some increase in sexual desire. What that means is that just thinking it might work made some women more horny -- this is known as the placebo effect.

Breast cancer drug Herceptin has been approved in Europe for use with hormonal therapy for postmenopausal patients with HER2 and hormone receptor positive metastatic disease.

Herceptin, made by Swiss drugmaker Roche Holding AG, is already approved in Europe for early and metastatic HER2-positive breast cancer.

This new approval is based on data from an international late stage clinical trial showing the combination of Herceptin with hormonal therapy doubled the median progression-free survival time.

A new study published in the Journal of the National Cancer Institute suggests that postmenopausal women who eat healthy amounts of plant food rich in estrogen-like compounds called lignans may reduce their risk of developing breast cancer.

Lignans are found only in certain foods. Lignans only come from plant foods, such as whole grains, nuts, seeds, and beans. The best source of lignans are flax seeds.

The study, including over fifty eight thousand French women, showed that they had a 17 percent lower risk of developing breast cancer if lignans were part of their diet compared with women having the lowest dietary lignan levels.

A diet containing lots of plant food is hypothesized to offer a breast cancer prevention strategy, however, if you have already been diagnosed with estrogen receptor positive breast cancer it is best to talk to your doctor before going on any high lignan diet. The jury is still out on whether it can help with lowering the risk of recurrence and if it is safe for ER positive breast cancers.

Findings from an international study suggest that women with a waist size of more than 34 inches are more likely to develop cancer of the womb than women who boast slimmer waistlines.

The study, funded in part by the British charity Cancer Research UK, sized up 223,000 women worldwide and determined that women with a waistline less than 31 inches have half the risk of developing womb cancer than their heavier counterparts.

There has been a significant rise in cases of womb cancer in Britain. And the link between the disease and weight gain is most prevalent among postmenopausal women who have never used hormone replacement therapy or the birth control pill.

According to the National Sizing Survey conducted in 2004, the average British woman now has a 34-inch waist. This is more than six inches bigger than the average size of a woman in the 1950s, says Dr. Lesley Walker of Cancer Research UK.

"Women are larger than they were when they existed on a wartime diet and were generally more active and this is having serious consequences," Walker says.

More than 6,000 women in the UK are diagnosed with womb cancer each year. The disease kills about 1,000 annually.

According to the results of an international study, postmenopausal women who have taken tamoxifen for early stage estrogen-receptor positive breast cancer for two to three years might increase their chances of survival by switching to newer breast cancer drugs called aromatase inhibitors.

Study researchers found this drug switch-up reduced the number of events linked to poor survival by 32 percent -- although no difference has been found in overall survival at this early point in the trial.

"These findings provide some limited evidence to advise all women being administered tamoxifen to switch, even though this approach is not devoid of potentially serious side effects," say experts at the National Cancer Institute.

Side effects appear to be minimal, however, and the up side of treatment with aromatase inhibitors is the fact that they don't seem to carry the risk of death from other causes like with tamoxifen, which can cause stroke or endometrial cancer.

This study is expected to be published in the March 15 issue of the journal Cancer.

Carrying extra weight is a risk factor for developing breast cancer. But it's not been clear how the timing of weight gain affects this risk. Evidence is mounting, though, and it's now believed that weight gain in adult life is more predictive of breast cancer risk than absolute body weight.

A new study, published in December's International Journal of Cancer, reveals a link between gaining weight in adulthood and an increased risk of breast cancer after menopause.

"We did find some suggestion that weight gain during the 30s and 40s, weight gain since a woman's first pregnancy and weight gain since menopause, especially for women with a longer time since menopause, may all be of importance in relation to postmenopausal breast cancer risk," report the researchers who followed 1,166 women with breast cancer and 2,105 without the disease.

A 70 percent increased risk was found among postmenopausal women who gained more than 60 pounds between age 20 and the onset of menopause. This was in comparison to women who gained less than 20 pounds during the same period of time. Overall, there was a four percent increase in breast cancer risk for each 11-pound increase in adult weight.

I'm coming up on my last year on tamoxifen. I often wonder if it would be beneficial to me to begin taking an aromatase inhibitor following my five years of tamoxifen. According to an article published in the journal Cancer, premenopausal women with breast cancer that has spread to at least four lymph nodes received the most benefit from aromatase inhibitors following treatment with tamoxifen. Postmenopausal women with cancer that has spread to three or less nodes only seem to get a 1-2 percent benefit from the addition of an aromatase inhibitor following tamoxifen.

I don't seem to fit in either category since I had premenopausal breast cancer with less than four lymph nodes positive. I also thought that if you are premenopausal that aromatase inhibitors were not beneficial at all and only postmenopausal women were able to take these drugs.

Aromatase inhibitors work by reducing the amount of estrogen your body makes. Your adrenal glands produce a substance called androstenedione, which gets converted into estrogen in tissues such as fat and muscle. The conversion requires the enzyme called aromatase. Aromatase inhibitors stop the conversion of androstenedione to estrogen. However, if your ovaries are still functioning then the body still will have estrogen that can help cancer to grow and the aromatase inhibitors will not stop the estrogen production of the ovaries.

The study that was done concluded - it appears that women who are premenopausal and those whose cancer has spread to four or more lymph nodes would derive greater benefit from the addition of aromatase agents following tamoxifen.

I am assuming that they mean if these premenopausal women are then put into a postmenopausal state, either happening by chemotherapy or shutting down the ovaries by injection or oophorectomy.

This is a confusing article that doesn't seem to make sense. Any insights?

Prescription drugs purchased online from Canadian pharmacies were intercepted before they reached the US, and after preliminary laboratory tests were found to be counterfeit. The U.S. Food and Drug Administration (FDA) is warning consumers who may have obtained prescription drugs from Mediplan Prescription Plus Pharmacy or Mediplan Global Health in Manitoba, Canada not to take the medication as it may not be safe.

The drugs in question are Lipitor, Diovan, Actonel, Nexium, Hyzaar, Ezetrol or Zetia, Crestor, Celebrex, Arimidex, and Propecia. Most of the drugs are prescribed for cholesterol disorders and high blood pressure; Actonel for osteoporosis in postmenopausal women; Nexium for gastroesophageal reflux disease; Celebrex for arthritis-related pain; Propecia for male-pattern baldness and Arimidex is a breast cancer chemoprevention medication.

Interestingly, the FDA conducted an investigation last year and discovered that nearly half of the imported drugs they confiscated from four selected countries were shipped to fill orders that consumers believed they were placing with Canadian pharmacies. The drugs did not come from Canada. According to the FDA, 85 percent actually came from 27 other countries around the globe. Buyer beware.

Hormonal Therapies: Making Decisions and Quality of Life After Breast Cancer is the next teleconference hosted by Living Beyond Breast Cancer (LBBC). Get the latest treatment strategies and learn about quality of life issues surrounding hormonal therapy during a free teleconference from 12 p.m to 1:30 p.m on Tuesday, September 26th.

Speaker Ruth Oratz, MD, FACP, associate professor of clinical medicine at the New York University School of Medicine will help you understand how hormonal therapy works and who should consider treatment. You can learn about aromatase inhibitors in treating breast cancer in postmenopausal women, the use of tamoxifen for premenopausal women and how to maintain bone health.

After the presentation, Dr. Oratz will invite you to participate in a 45 minute question and answer session. Register for the teleconference here.

When I first looked at my pathology report more than 18 months ago, it made little sense. Terms like Bloom Richardson Score and margins and Her2Neu were as foreign to me as the breast cancer that somehow invaded my body. So I read it over and over again and was eventually able to identify the basic meaning hidden within the four pages that detailed my disease. As it turned out, this report was my map. It led me in various directions for various treatments. It contained some roadblocks. It was sometimes confusing. And sometimes I got lost. There were some good and not-so-good stops along the way. And in the end, I reached my final destination -- in the land survival. And this is where I hope to stay. For a long time.

My map is not necessary anymore -- although I still look back at it. I've found that it makes more sense now that time has passed. I can interpret it more objectively, with more perspective and less emotion and fear. I am still learning about the disease that was removed from my breast. And I am realizing there was a lot I never really knew -- like these seven subjects -- when breast cancer was new and fresh and debilitating.

The International Aromatase Inhibitor Expert Panel, a panel of 24 breast cancer specialists from Europe, the USA, Australia, China and Brazil, has reconfirmed that aromatase inhibitors (AIs) such as Arimidex, are superior to Tamoxifen in the chemoprevention drug treatment of postmenopausal women with newly diagnosed hormone-sensitive, early breast cancer.

"Over the last three years, there has been an influx of new information about the use of aromatase inhibitors in early breast cancer, and while this is great news, it has created a great deal of confusion. This guidance helps to clarify considerations for use of AIs in everyday practice. These data provide the evidence that support using an aromatase inhibitor at the earliest opportunity," commented panel member Dr. Aman Buzdar, professor of medicine for the department of breast medical oncology at The University of Texas M. D. Anderson Cancer Center in Houston.

While aromatase inhibitors are better tolerated and cause less potentially life-threatening side effects than Tamoxifen, Als do increase bone fracture risk -- which is said to be a problem that can be watched for and effectively treated. However, the long-term use of aromatase inhibitors and the effects on heart disease are yet to be determined.

Diahann Carroll, an actress who started her career back in the 50s, and Oscar nominee who has starred in such TV shows as Dynasty, will be reaching out to older women in an effort to raise breast cancer awareness and the breast cancer risks they face. Carroll, who was diagnosed at the age of 63, spoke with CBS The Early Show's Julie Chen about the shock of being diagnosed with breast cancer when she had no family history for the disease. At the time, she said she was much more concerned about preventing age-related diabetes and heart disease.

According to recent surveys, so are most postmenopausal women. The results of a new Harris Interactive survey of nearly 20,000 women revealed that only 37 percent of women 55 or older are concerned about developing breast cancer as they age. The findings also show that three out of every four women don't know that being over 50 is the greatest risk for developing breast cancer. In fact, most women believe that the greatest risk factors are having a family member with the disease and inherited genetic mutations.

Carroll has been hired by Eli Lilly as the spokesperson for the launch the Strength in Knowing: The Facts and Fiction of Breast Cancer Risk campaign and website created to educate postmenopausal women about the real breast cancer risk factors. In the new fall TV season, Carroll will become a part of Grey's Anatomy. She would not give Chen any details. You can watch The CBS The Early Show interview with Carroll here.